This application note evaluates the in vivo performance of Touchlight’s doggybone DNA™ (dbDNA™) compared with conventional plasmid DNA when delivered using Sartorius Polyplus non‑viral delivery reagents. The study investigates how…
Read More
Explore how cell‑free DNA z‑dbDNA™ offers a faster, more flexible alternative to plasmid DNA for making RNA vaccines and therapies.
Read More
As cell and gene therapy scales, DNA choice matters. Learn the advantages of cell‑free DNA vs pDNA in this Q&A with Touchlight’s CSO.
Read More
Touchlight is proud to announce a strategic partnership with SVF Vaccines to progress SVF’s innovative Hepatitis B/D vaccine into clinical development.
Read More
This application note presents a comparative study of enzymatically manufactured doggybone DNA™ (dbDNA™) versus traditional plasmid DNA (pDNA) for lentiviral vector (LVV) production, using the FuGENE® 4K transfection reagent. The…
Read More
Discover how Touchlight’s novel circular DNA architectures—mbDNA™, sscDNA, hsscDNA, and dscDNA—enable precise, efficient gene insertion for next‑generation gene editing and non‑viral gene therapy.
Read More
Touchlight and New England Biolabs launch the EnClose™ Cell‑free dbDNA™ Synthesis Kit, enabling rapid, scalable, cell‑free production of high‑purity DNA for next‑generation mRNA, gene therapy, and vector development.
Read More
